The Supreme Court unanimously rejected a bid to ramp up restrictions on access to mifepristone, part of a two drug regimen frequently used to cause abortions.
In a 9 to 0 ruling authored by Justice Brett Kavanaugh, the high court concluded the group of anti-abortion doctors that brought the case forward lacked standing to challenge the Food and Drug Administration’s prior regulatory approval of the pill.
“Those standing allegations suffer from the same problema lack of causation. The causal link between FDAs regulatory actions and those alleged injuries is too speculative or otherwise too attenuated to establish standing,” Kavanaugh wrote in his opinion.
Back in March when the Supreme Court heard oral arguments in the matter, justices sounded deeply skeptical about upending the FDA’s approval of mifepristone.
FDA v. Alliance for Hippocratic Medicine marks the high court’s most consequential decision on abortion since the overturn of Roe v. Wade in 2022. The Supreme Court is also weighing a separate abortion case out of Idaho.
This is a developing story. Refresh for updates.
